• Publications
  • Influence
Modelling of individual pharmacokinetics for computer-aided drug dosage.
TLDR
A pharmacokinetic model and statistical methodology is presented which is designed to provide the basis for a clinically useful computer program to suggest optimal dosage regimens for a number of drugs for individual patients. Expand
  • 369
  • 14
LINDAU'S DISEASE. REVIEW OF THE LITERATURE AND STUDY OF A LARGE KINDRED.
Abstract The history of Lindau's disease is reviewed, and current knowledge of the multisystemic involvement and the clinical, laboratory and roentgenologic features are outlined. Ten proved casesExpand
  • 546
  • 11
Lidocaine disposition kinetics in monkey and man; II. Effects of hemorrhage and sympathomimetic drug administration
Lidocaine disposition kinetics in normal and hemorrhaged rhesus monkeys was studied. During bleeding there was a reduction in distribution and clearance of lidocaine, along with an increase inExpand
  • 120
  • 5
Lidocaine disposition kinetics in monkey and man; I. Prediction by a perfusion model
Lidocaine pharmacokinetics are described in the unanesthetized restrained rhesus monkey after bolus and steady infusion. Simultaneous measurements of systemic and regional blood flows and tissueExpand
  • 222
  • 4
Mechanisms of inflammation
Fifteen years ago Sutherland and RaIl identified adenosine 3',5'‐monophosphate (cyclic AMP) as an intracellular “second messenger” mediating epinephrine's stimulation of hepatic glycogenolysis.20, 21Expand
  • 58
  • 4
Beta-adrenergic receptors on human suppressor, helper, and cytolytic lymphocytes.
Using the radioligand beta-adrenergic blocker [125I]cyanopindolol (ICYP), we have characterized the beta-adrenergic receptors on Leu 3+ (T helper [TH]), Leu 2+, 9.3- (T suppressor [Ts]) and Leu 2+,Expand
  • 196
  • 3
DISPOSITION KINETICS OF LIDOCAINE IN NORMAL SUBJECTS *
The use of intravenous (i.v.) lidocaine for the control of ventricular arrhthmias has made it necessary to learn more about the disposition kinetics of this drug, and from such information toExpand
  • 194
  • 3
Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage.
To determine the association of duration of warfarin anticoagulant therapy after hospitalization for venous thromboembolism with the probability of recurrent thromboembolism and with the risks ofExpand
  • 149
  • 3
Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin.
We previously showed that the risk of major hemorrhage in patients with venous thromboembolism treated with warfarin was strongly related to duration of anticoagulant therapy. We here report theExpand
  • 78
  • 3
...
1
2
3
4
5
...